Inhibrx Shares Fall After Expanding Loan Agreement to $500M

Dow Jones07-16

Shares of Inhibrx Biosciences fell after the clinical-stage biopharmaceutical company said it expanded its loan agreement with Oxford Finance to $500 million.

The stock was down 4.4% to $87.22 in recent trading, but rose 10% since the start of the year.

Inhibrx said the expansion adds $325 million to its initial loan of $175 million.

In connection with the loan, the company issued the lenders warrants to purchase 21,457 shares of common stock at a strike price of $93.21 per share.

Chief Financial Officer Kelly Deck said the loan would push momentum in advancing ozekibart and INBRX-106, precision engineered immunotherapies, as the company awaits key upcoming data readouts.

Write to Grace Yoon at grace.yoon@wsj.com

(END) Dow Jones Newswires

July 16, 2026 10:29 ET (14:29 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2651400074?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 22:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651400074","market":"sg","top_or_hot":-1,"title":"Inhibrx Shares Fall After Expanding Loan Agreement to $500M","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> fell after the clinical-stage biopharmaceutical company said it expanded its loan agreement with Oxford Finance to $500 million. \n</p>\n<p>\n  The stock was down 4.4% to $87.22 in recent trading, but rose 10% since the start of the year. \n</p>\n<p>\n  Inhibrx said the expansion adds $325 million to its initial loan of $175 million. \n</p>\n<p>\n  In connection with the loan, the company issued the lenders warrants to purchase 21,457 shares of common stock at a strike price of $93.21 per share. \n</p>\n<p>\n  Chief Financial Officer Kelly Deck said the loan would push momentum in advancing ozekibart and INBRX-106, precision engineered immunotherapies, as the company awaits key upcoming data readouts. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 16, 2026 10:29 ET (14:29 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inhibrx Shares Fall After Expanding Loan Agreement to $500M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInhibrx Shares Fall After Expanding Loan Agreement to $500M\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-16 22:29</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/INBX\">Inhibrx Biosciences</a> fell after the clinical-stage biopharmaceutical company said it expanded its loan agreement with Oxford Finance to $500 million. \n</p>\n<p>\n  The stock was down 4.4% to $87.22 in recent trading, but rose 10% since the start of the year. \n</p>\n<p>\n  Inhibrx said the expansion adds $325 million to its initial loan of $175 million. \n</p>\n<p>\n  In connection with the loan, the company issued the lenders warrants to purchase 21,457 shares of common stock at a strike price of $93.21 per share. \n</p>\n<p>\n  Chief Financial Officer Kelly Deck said the loan would push momentum in advancing ozekibart and INBRX-106, precision engineered immunotherapies, as the company awaits key upcoming data readouts. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 16, 2026 10:29 ET (14:29 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INBX","symbol_name":"Inhibrx Biosciences","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2651400074","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651400074","pubTimestamp":1784212140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Inhibrx Biosciences fell after the clinical-stage biopharmaceutical company said it expanded its loan agreement with Oxford Finance to $500 million.The stock was down 4.4% to $87.22 in recent trading, but rose 10% since the start of the year.Inhibrx said the expansion adds $325 million to its initial loan of $175 million.In connection with the loan, the company issued the lenders warrants to purchase 21,457 shares of common stock at a strike price of $93.21 per share.Chief Financial Officer Kelly Deck said the loan would push momentum in advancing ozekibart and INBRX-106, precision engineered immunotherapies, as the company awaits key upcoming data readouts.Write to Grace Yoon at grace.yoon@wsj.com Dow Jones NewswiresJuly 16, 2026 10:29 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INBX":"Inhibrx Biosciences","BK4139":"生物科技"},"translate_title":"Inhibrx 将贷款协议扩大至 5 亿美元后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INBX":1.5},"content_text":"Shares of Inhibrx Biosciences fell after the clinical-stage biopharmaceutical company said it expanded its loan agreement with Oxford Finance to $500 million. \n\n\n  The stock was down 4.4% to $87.22 in recent trading, but rose 10% since the start of the year. \n\n\n  Inhibrx said the expansion adds $325 million to its initial loan of $175 million. \n\n\n  In connection with the loan, the company issued the lenders warrants to purchase 21,457 shares of common stock at a strike price of $93.21 per share. \n\n\n  Chief Financial Officer Kelly Deck said the loan would push momentum in advancing ozekibart and INBRX-106, precision engineered immunotherapies, as the company awaits key upcoming data readouts. \n\n\n \n\n\n  Write to Grace Yoon at grace.yoon@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 16, 2026 10:29 ET (14:29 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651400074","isCrawlerRequest":true}